Identification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from the lung carcinoma antigen, Lengsin - PubMed (original) (raw)
doi: 10.3892/ijo.2011.1089. Epub 2011 Jun 17.
Kazutaka Horie, Toshiaki Yoshikawa, Manami Shimomura, Yamato Kikuchi, Noriko Sakemura, Shiro Suzuki, Daisuke Nobuoka, Yoshihiko Hirohashi, Toshihiko Torigoe, Kenji Harada, Hideo Takasu, Noriyuki Sato, Tetsuya Nakatsura
Affiliations
- PMID: 21687943
- DOI: 10.3892/ijo.2011.1089
Identification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from the lung carcinoma antigen, Lengsin
Munehide Nakatsugawa et al. Int J Oncol. 2011 Oct.
Abstract
Lengsin is an eye lens protein with a glutamine synthetase domain. We previously identified this protein as a lung carcinoma antigen through cDNA microarray analysis. Lengsin protein is overexpressed irrespective of the histological type of lung carcinoma, but not in normal tissues other than the lens. Therefore, to significantly extend the use of Lengsin-based T-cell immunotherapies for the treatment of patients with lung carcinoma, we searched for HLA-A*0201-restricted epitopes from this protein by screening predicted Lengsin-derived candidate peptides for the induction of tumor-reactive CTLs. Four Lengsin-derived peptides were selected by computerized algorithm based on a permissive HLA-A*0201 binding motif, and were used to immunize HLA-A*0201 transgenic (HHD) mice. Two of the immunizing peptides, Lengsin(206-215)(FIYDFCIFGV) and Lengsin(270-279)(FLPEFGISSA), induced peptide-specific cytotoxic T lymphocytes (CTLs) in HHD mice, and thus were used to stimulate human peripheral blood lymphocytes in vitro. Lengsin(206-215) and Lengsin (270-279) also induced human peptide-specific CTLs, and we were able to generate Lengsin(206-215)- and Lengsin(270-279)-specific CTL clones. The Lengsin(270-279)-specific CTL clone specifically recognized peptide-pulsed T2 cells, COS-7 cells expressing HLA-A*0201 and Lengsin, and HLA-A*0201+/Lengsin+ lung carcinoma cells in an HLA-A*0201-restricted manner. On the other hand, the Lengsin(206-215)-specific CTL clone failed to recognize HLA-A*0201+/Lengsin+ target cells in the absence of cognate peptide. These results suggest that Lengsin(270-279) is naturally processed and presented by HLA-A*0201 molecules on the surface of lung carcinoma cells and may be a new target for antigen-specific T-cell immunotherapy against lung cancer.
Similar articles
- HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M, Hirata S, Irie A, Senju S, Nakatsura T, Komori H, Ikuta Y, Yokomine K, Imai K, Inoue M, Harada K, Mori T, Tsunoda T, Nakatsuru S, Daigo Y, Nomori H, Nakamura Y, Baba H, Nishimura Y. Harao M, et al. Int J Cancer. 2008 Dec 1;123(11):2616-25. doi: 10.1002/ijc.23823. Int J Cancer. 2008. PMID: 18770861 - Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene.
Yoshimura M, Tada Y, Ofuzi K, Yamamoto M, Nakatsura T. Yoshimura M, et al. Oncol Rep. 2014 Jul;32(1):33-9. doi: 10.3892/or.2014.3198. Epub 2014 May 19. Oncol Rep. 2014. PMID: 24842630 Free PMC article. - Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S, Azuma K, Komatsu N, Ito M, Maeda Y, Ishihara Y, Itoh K. Shichijo S, et al. Clin Cancer Res. 2004 Sep 1;10(17):5828-36. doi: 10.1158/1078-0432.CCR-04-0350. Clin Cancer Res. 2004. PMID: 15355913 - Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
Nishimura Y, Tomita Y, Yuno A, Yoshitake Y, Shinohara M. Nishimura Y, et al. Cancer Sci. 2015 May;106(5):505-11. doi: 10.1111/cas.12650. Epub 2015 Apr 1. Cancer Sci. 2015. PMID: 25726868 Free PMC article. Review. - Cytotoxic T cell responses against immunoglobulin in malignant and normal B cells: implications for tumor immunity and autoimmunity.
Gricks CS, Gribben JG. Gricks CS, et al. Curr Pharm Des. 2003;9(23):1889-903. doi: 10.2174/1381612033454333. Curr Pharm Des. 2003. PMID: 12871193 Review.
Cited by
- A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients.
Hannani D, Leplus E, Laurin D, Caulier B, Aspord C, Madelon N, Bourova-Flin E, Brambilla C, Brambilla E, Toffart AC, Laulagnier K, Chaperot L, Plumas J. Hannani D, et al. Int J Mol Sci. 2023 Jan 18;24(3):1897. doi: 10.3390/ijms24031897. Int J Mol Sci. 2023. PMID: 36768214 Free PMC article. - Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.
Alarcon NO, Jaramillo M, Mansour HM, Sun B. Alarcon NO, et al. Pharmaceutics. 2022 Jul 11;14(7):1448. doi: 10.3390/pharmaceutics14071448. Pharmaceutics. 2022. PMID: 35890342 Free PMC article. Review. - Genetic variants in glutamine metabolic pathway genes predict cutaneous melanoma-specific survival.
Chen K, Liu H, Liu Z, Bloomer W, Amos CI, Lee JE, Li X, Nan H, Wei Q. Chen K, et al. Mol Carcinog. 2019 Nov;58(11):2091-2103. doi: 10.1002/mc.23100. Epub 2019 Aug 22. Mol Carcinog. 2019. PMID: 31435991 Free PMC article. - Altered glutamine metabolism and therapeutic opportunities for lung cancer.
Mohamed A, Deng X, Khuri FR, Owonikoko TK. Mohamed A, et al. Clin Lung Cancer. 2014 Jan;15(1):7-15. doi: 10.1016/j.cllc.2013.09.001. Epub 2013 Nov 13. Clin Lung Cancer. 2014. PMID: 24377741 Free PMC article. Review. - Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide.
Tada Y, Yoshikawa T, Shimomura M, Sawada Y, Sakai M, Shirakawa H, Nobuoka D, Nakatsura T. Tada Y, et al. Int J Oncol. 2013 Oct;43(4):1019-26. doi: 10.3892/ijo.2013.2044. Epub 2013 Jul 31. Int J Oncol. 2013. PMID: 23903757 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials